August 5, 2025 — ImmunityBio, Inc. (NASDAQ: IBRX) announced its financial results for the fiscal quarter and six months ended June 30, 2025, revealing a 60% revenue increase in the second quarter, reaching $26.4 million compared to $16.5 million in the first quarter. The growth is attributed to the commercial success of ANKTIVA in combination with BCG for BCG-unresponsive NMIBC with carcinoma in situ. First-half sales totaled $42.9 million, a 246% increase in unit volume since J-code approval. The company’s cash, cash equivalents, and marketable securities stood at $153.7 million as of June 30, 2025.
President and CEO of ImmunityBio, Richard Adcock, noted the robust demand for ANKTIVA across U.S. urology practices, citing its ease of storage and administration. With commercial authorization in the UK, the company is evaluating its market strategy. Additionally, their recombinant BCG therapeutic has been safely administered to over 150 patients under an expanded access protocol to address the BCG shortage in the U.S.
Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio, Dr. Patrick Soon-Shiong, stated the company has begun global expansion of key clinical trials, including those for BCG-naïve NMIBC and second-line lung cancer. Enrollment has also commenced across multiple trials to validate a novel lymphopenia rescue agent.
ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, approved by the FDA in 2024 and by UK MHRA in 2025 for BCG-unresponsive non-muscle invasive bladder cancer CIS with or without papillary tumors.
Second-Quarter Financial Highlights:
- Product revenue increased by $25.4 million compared to the same period last year.
- Research and development expenses rose by $4.1 million to $55.2 million.
- Selling, general, and administrative expenses decreased by $6.9 million to $42.3 million.
- Net loss attributable to ImmunityBio common stockholders was $92.6 million, compared to $134.6 million in the previous year.
Six-Month Financial Highlights:
- Product revenue increased by $41.9 million compared to the same period last year.
- R&D expense decreased $1.0 million to $103.5 million.
- SG&A expense decreased $16.1 million to $75.0 million.
- Net loss attributable to ImmunityBio common stockholders was $222.2 million, compared to $268.7 million in the previous year.
Contact:
Source: ImmunityBio
